CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 2, 2019

Primary Completion Date

February 28, 2021

Study Completion Date

September 30, 2021

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

CM082 plus JS001

CM082:150mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AnewPharma

INDUSTRY

NCT03848611 - CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). | Biotech Hunter | Biotech Hunter